Apr 18 |
NRx Pharmaceuticals receives Nasdaq notice on demonstrating compliance with bid price requirement
|
Apr 18 |
NRx Pharmaceuticals (NASDAQ:NRXP) Receives Notice from Nasdaq that the Company has Demonstrated Compliance with the Bid Price Requirement
|
Apr 18 |
NRx Pharmaceuticals, Inc. Announces Pricing of $2.0 Million Underwritten Public Offering of Common Stock
|
Apr 17 |
NRx Pharmaceuticals announces proposed underwritten public offering of common stock
|
Apr 17 |
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces New Data on NRX-101 Demonstrating No Damage to Intestinal and Vaginal Flora in Validated Rodent Models Compared to Standard Antibiotics: Potential Implications for Avoidance of C. Difficile infections
|
Apr 15 |
(NRXP) - Analyzing NRX Pharmaceuticals's Short Interest
|
Apr 15 |
NRx Pharmaceuticals (NASDAQ:NRXP) Announces Development of New, Proprietary Formulation of HTX-100 (IV Ketamine)
|
Apr 8 |
NRx Pharmaceuticals (NASDAQ:NRXP) Announces Data-Lock of Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression
|
Apr 1 |
NRX Pharmaceuticals, Inc. (NRXP) Q4 2023 Earnings Call Transcript
|
Apr 1 |
NRx Pharmaceuticals reports Q4 results
|